Oregon Bio has launched an occasional series called Voice of Academia and today, we’re bringing Part 2 (see Part 1 here) of our talk with University of Oregon professor and faculty member

(Portland, Ore.) – With hiring and growth happening at dozens of scientific, manufacturing and biotech companies in the Pacific Northwest, the Oregon Bioscience Association has retooled its myriad educational workforce

June 29, 2020 In the weeks since we learned of remdesivir’s potential against COVID-19, one topic has attracted more speculation than any other: what price we might set for the

Oregon Bio has launched an occasional series called Voice of Academia to spotlight academic partnerships and commercialization opportunities as well as advances in research in the Pacific Northwest’s bioscience and medical technology

Washington, DC – (June 26, 2020) – The Biotechnology Innovation Organization (BIO) today announced winners of the Start-up Stadium competition held during BIO Digital in June. Pre-recorded presentation videos submitted by 30 finalists

The show will go on!” says AdvaMed CEO Scott Whitaker WASHINGTON, D.C. – The MedTech Conference, powered by AdvaMed, promises to continue its tradition of providing world-class programming for the medical

● 8-Minute, Low-Cost Diagnostic Test for Sickle Cell Disease (SCD) Among First Approved Tests ● Includes a One-Minute Malaria Test with Solutions to Follow for Other Health Priorities Officials from

Financing Co-Led by ARCH Venture Partners and Cowen Healthcare Investments Deep Leadership Expertise in Thyroid Hormone Biology, Medicinal Chemistry and Neurology SAN DIEGO–(BUSINESS WIRE)–Autobahn Therapeutics is launching to create the

Board of directors selects interim director Heather Ellis to take full time role June 10, 2020 — PORTLAND, Ore. — The board of directors for the Oregon Translational Research and

June 10, 2020 ERT, the global leader in clinical endpoints data collection, today announced the acquisition of APDM Wearable Technologies (APDM, Inc.), a next-generation provider of wearables and digital biomarkers.

Phase Ib study to combine UbiVac’s DRibble® Platform Vaccine, DPV-001 with anti-OX40 (BMS-986178) and Opdivo (nivolumab) to test hypothesis that this combination will augment anticancer immunity in advanced triple negative breast

Foster City, Calif., May 22, 2020 – Gilead Sciences today issued the following statement from Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences, on data from the National Institute